The efficacy of a pharmaceutical drug is intrinsically linked to the quality of its constituent components, particularly the active pharmaceutical ingredient (API) and its synthetic intermediates. 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone, identified by CAS Number 179688-29-0, plays a pivotal role in the synthesis of Erlotinib, a critical medication for cancer patients. NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing this intermediate with precise specifications, understanding that each property contributes to the overall success of the final product.

The physical appearance of 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone is typically a white solid. This characteristic is not only for visual identification but also indicative of its purity and processing state. A defined melting point range, noted as 185-189°C, is a key quality indicator. This parameter helps confirm the compound's identity and purity, as deviations can suggest the presence of impurities or structural variations. The boiling point and flash point data, while less critical for direct handling of the solid, provide vital safety information for process design and risk assessment during manufacturing. These parameters are carefully managed and documented by NINGBO INNO PHARMCHEM CO.,LTD. to ensure safe and efficient handling and synthesis.

Furthermore, the molecular formula C14H18N2O5 and a molecular weight of 294.30 highlight the specific chemical composition that makes this compound an ideal building block for Erlotinib. The presence of the quinazolinone ring system and the bis(2-methoxyethoxy) substituents are crucial for the subsequent chemical transformations that lead to the final drug molecule. As a manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. ensures that its synthesis processes are optimized to yield this exact structure with minimal side products or impurities. This meticulous approach to synthesis and quality assurance is what allows pharmaceutical companies to buy with confidence, knowing they are obtaining a reliable ingredient.

The consistent quality and well-defined properties of 6,7-Bis(2-methoxyethoxy)-4(3H)-quinazolinone from NINGBO INNO PHARMCHEM CO.,LTD. empower pharmaceutical developers and manufacturers. By understanding and relying on these specific properties, researchers and production teams can optimize their synthesis strategies, ensure batch-to-batch consistency, and ultimately contribute to the development of effective cancer treatments.